OTC · Biotechnology

Paradigm Biopharmaceuticals Limited (PBIGF) Stock

$0.12 -5.44% OTC: PBIGF Healthcare

Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome.

Valuation

MetricValue
Price$0.12
Market Cap$52.01M
P/E Ratio-1.91
P/B Ratio11.73
P/S Ratio1216.38
EPS (TTM)$-0.06
52-Week High$0.35
52-Week Low$0.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-265.55%
ROA-155.88%
ROCE-589.85%
Gross Margin-161.09%
Operating Margin-86793.89%
Net Margin0.00%
Debt/Equity0.17
Current Ratio1.31

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-43.0M$-48.0M$-60.0M$-65.0M$-23.0M
Net Profit$-34.0M$-39.0M$-52.0M$-59.0M$-19.0M
EPS$-0.16$-0.16$-0.18$-0.20$-0.06
Op Margin-210124.4%-60498.8%-128497.1%-99077.5%-43910.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$85.0M$51.0M$67.0M$27.0M$25.0M
Total Liabilities$7.0M$8.0M$13.0M$4.0M$3.0M
Cash$71.0M$40.0M$56.0M$18.0M$17.0M
Borrowings$1.0M$1.0M$0$0$0

Latest News

Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight GlobeNewswire · Jun 15, 2026 Market Sentiment Around Loss-Making Paradigm Biopharmaceuticals Limited (ASX:PAR) Simply Wall St. · May 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-32.0M$-45.0M$-66.0M$-16.0M
Investing Cash Flow$1.0M$0$0$66.0M$0
Financing Cash Flow$0$0$-4.0M$0$0
Net Cash Flow$-33.0M$-31.0M$17.0M$-39.0M$-1.0M
Free Cash Flow$-35.0M$-32.0M$-45.0M$-66.0M$-16.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-1.47
FCF Yield-10.55%
Quick Ratio1.31
Interest Coverage-29.37
Return 1Y-47.51%
Return 3Y-80.57%
Return 5Y—

Ownership

Insiders Held10.12%
Institutions Held6.82%
Institutions Float Held7.59%
Institutional HolderSharesReport Date
DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series60,8172026-04-30
Dimensional ETF Trust-Dimensional International Small Cap ETF54,5222026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AURXNuo Therapeutics, Inc. $1.00 +11.11% -20.00 $48.41M 0.00%
IUGNFImugene Limited $0.10 +0.00% -0.40 $41.60M 0.00%
KNTPFKintor Pharmaceutical Limited $0.23 -0.20% -3.33 $107.85M 0.00%
MSCLFSatellos Bioscience Inc. $6.25 +11.81% -1.75 $96.62M 0.00%
ORXOFOrexo AB (publ) $1.55 +0.00% -1.65 $54.45M 0.00%

About Paradigm Biopharmaceuticals Limited

Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.

Paradigm Biopharmaceuticals Limited is headquartered in AU.

Paradigm Biopharmaceuticals Limited (PBIGF) stock trades at $0.12 with a market capitalization of $52.01M. The stock is valued at a price-to-earnings (P/E) ratio of -1.91, price-to-book of 11.73, price-to-sales of 1216.38. Over the past 52 weeks the stock has ranged between $0.10 and $0.35, and currently trades 65.7% below its 52-week high.

On profitability, Paradigm Biopharmaceuticals Limited generates a return on equity (ROE) of -265.55%, return on capital employed of -589.85%, an operating margin of -86793.89%, a net profit margin of 0.00%.

Official website: www.paradigmbiopharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides